Trastuzumab pamirtecan versus chemotherapy in patients with previously treated, human epidermal growth factor receptor 2 (HER2)-expressing, recurrent endometrial cancer: the phase 3 Fern-EC-01 trial (BNT323-01/GOG-3105/ENGOT-EN25)
Trastuzumab pamirtecan versus chemotherapy in patients with previously treated, human epidermal growth factor receptor 2 (HER2)-expressing, recurrent endometrial cancer: the phase 3 Fern-EC-01 trial (BNT323-01/GOG-3105/ENGOT-EN25). // International Journal of Gynecological Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S1048891X26012338?dgcid=rss_sd_all
Trastuzumab pamirtecan versus chemotherapy in patients with previously treated, human epidermal growth factor receptor 2 (HER2)-expressing, recurrent endometrial cancer: the phase 3 Fern-EC-01 trial (BNT323-01/GOG-3105/ENGOT-EN25). International Journal of Gynecological Cancer. https://www.sciencedirect.com/science/article/pii/S1048891X26012338?dgcid=rss_sd_all
“Trastuzumab pamirtecan versus chemotherapy in patients with previously treated, human epidermal growth factor receptor 2 (HER2)-expressing, recurrent endometrial cancer: the phase 3 Fern-EC-01 trial (BNT323-01/GOG-3105/ENGOT-EN25).” International Journal of Gynecological Cancer.
@article{article100382,
title = {Trastuzumab pamirtecan versus chemotherapy in patients with previously treated, human epidermal growth factor receptor 2 (HER2)-expressing, recurrent endometrial cancer: the phase 3 Fern-EC-01 trial (BNT323-01/GOG-3105/ENGOT-EN25)},
journal = {International Journal of Gynecological Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S1048891X26012338?dgcid=rss_sd_all}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment